GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuno-Biological Laboratories Co Ltd (TSE:4570) » Definitions » Earnings per Share (Diluted)

Immuno-Biological Laboratories Co (TSE:4570) Earnings per Share (Diluted) : 円20.04 (TTM As of Sep. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Immuno-Biological Laboratories Co Earnings per Share (Diluted)?

Immuno-Biological Laboratories Co's Earnings per Share (Diluted) for the three months ended in Sep. 2024 was 円0.00. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was 円20.04.

Immuno-Biological Laboratories Co's EPS (Basic) for the three months ended in Sep. 2024 was 円0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2024 was 円20.05.

Immuno-Biological Laboratories Co's EPS without NRI for the three months ended in Sep. 2024 was 円0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2024 was 円19.46.

During the past 13 years, Immuno-Biological Laboratories Co's highest 3-Year average EPS without NRI Growth Rate was 36.20% per year. The lowest was -210.50% per year. And the median was -15.00% per year.


Immuno-Biological Laboratories Co Earnings per Share (Diluted) Historical Data

The historical data trend for Immuno-Biological Laboratories Co's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuno-Biological Laboratories Co Earnings per Share (Diluted) Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -76.00 -34.23 -27.78 -31.10 20.05

Immuno-Biological Laboratories Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.69 -0.67 17.84 -

Competitive Comparison of Immuno-Biological Laboratories Co's Earnings per Share (Diluted)

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuno-Biological Laboratories Co's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's PE Ratio falls into.


;
;

Immuno-Biological Laboratories Co Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Immuno-Biological Laboratories Co's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (A: Mar. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(186.694-0)/9.313
=20.05

Immuno-Biological Laboratories Co's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2024 is calculated as

Diluted Earnings Per Share (Q: Sep. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(0-0)/9.313
=0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円20.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Immuno-Biological Laboratories Co  (TSE:4570) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Immuno-Biological Laboratories Co Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Immuno-Biological Laboratories Co's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuno-Biological Laboratories Co Business Description

Traded in Other Exchanges
N/A
Address
1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.

Immuno-Biological Laboratories Co Headlines

No Headlines